Deerfield commits $100M to establish translational research alliance with Harvard

Tuesday, March 12, 2019 - 23:40 in Health & Medicine

Harvard University and Deerfield Management, a health care investment firm, have established a major strategic R&D alliance to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield has committed $100 million in initial funding to support the alliance. Spearheaded by the Harvard Office of Technology Development (OTD), the alliance is expected to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation. “We envision the Harvard-Deerfield collaboration as a powerful means to fuel translational research across the University, enabling promising innovations to advance beyond their laboratory roots,” said Harvard Provost Alan M. Garber. “By working with an alliance partner who is prepared to support early stage research and to invest in the success of preclinical and clinical-stage commercial development, we’re enhancing the opportunities for Harvard’s life-changing innovations to reach patients...

Read the whole article on Harvard Science

More from Harvard Science

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net